SCHEMBL810552

SCHEMBL810552

Cc1ccc(Sc2ccc(Oc3ccccc3)cc2)c(N)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 7/20 0.49
SLC6A3 Q01959 6/20 0.49
SLC6A2 P23975 6/20 0.49
ALDH1A1 P00352 5/20 0.48
MAPT P10636 4/20 0.48
HPGD P15428 2/20 0.48
ALOX15 P16050 2/20 0.48
MAPK1 P28482 2/20 0.48
HSD17B10 Q99714 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
KDM4E B2RXH2 1/20 0.48
LMNA P02545 1/20 0.48
TDP1 Q9NUW8 3/20 0.46
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
GAA P10253 2/20 0.42
MAOA P21397 1/20 0.42
TEAD4 Q15561 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL810752 0.85 SLC6A4 (0.58) SLC6A4SLC6A3SLC6A2ALDH1A1MAPT
SCHEMBL810329 0.83 ALDH1A1 (0.55) SLC6A4SLC6A3SLC6A2ALDH1A1MAPT
SCHEMBL810664 0.82 ALDH1A1 (0.59) SLC6A4SLC6A3SLC6A2ALDH1A1MAPT
SCHEMBL2960428 0.79 MAPT (0.48) SLC6A4SLC6A3SLC6A2ALDH1A1MAPT
SCHEMBL14176624 0.76 HTR1A (0.43) SLC6A4ALDH1A1MAPTHPGDALOX15
SCHEMBL11957592 0.76 MAPT (0.46) SLC6A4SLC6A3SLC6A2ALDH1A1MAPT
SCHEMBL25969513 0.76 ALDH1A1 (0.61) ALDH1A1MAPTMAPK1L3MBTL1TDP1
SCHEMBL810286 0.76 ALDH1A1 (0.56) SLC6A4SLC6A3SLC6A2ALDH1A1MAPT
SCHEMBL809598 0.76 ALDH1A1 (0.54) SLC6A4SLC6A3SLC6A2ALDH1A1MAPT
SCHEMBL2970197 0.74 SLC6A2 (0.57) SLC6A4SLC6A3SLC6A2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338605-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2012-12-25 US disclosed
EP-1971611-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2012-10-10 EP disclosed
CN-102702194-A Anti-viral compounds ABBOTT LAB 2012-10-03 CN disclosed
EP-2345652-A1 Antiviral compounds Abbott Laboratories (US) 2011-07-20 EP disclosed
US-7915411-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2011-03-29 US disclosed
US-20100256139-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2010-10-07 US disclosed
EP-1979349-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2010-07-28 EP disclosed
US-7763731-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2010-07-27 US disclosed
EP-1979349-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-10-15 EP disclosed
EP-1971611-A1 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-09-24 EP disclosed
US-20070232645-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed
US-20070197558-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-08-23 US disclosed
WO-2007081517-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-19 WO disclosed
WO-2007076035-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197558-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 SLC6A4 4037/4885SLC6A3 3970/4885SLC6A2 4033/4885
US-20070232645-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 SLC6A4 4037/4885SLC6A3 3970/4885SLC6A2 4033/4885
US-20100256139-A1 Anti-Viral Compounds HAVCR2, MAVS, EIF2AK2 SLC6A4 4037/4885SLC6A3 3970/4885SLC6A2 4033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.